A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy

NCT01243268 · clinicaltrials.gov ↗

COMPLETED

Status

674

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: Twynsta tablet

Sponsor

Boehringer Ingelheim